Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
88 studies found for:    myeloma and velcade | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine, Bortezomib, Prednisone
2 Recruiting Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
Conditions: Multiple Myeloma;   High-Risk Cancer
Intervention: Drug: Bortezomib following nonmyeloablative allogeneic transplant
3 Recruiting Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Auto Stem Cell Transplant
Intervention: Drug: Bortezomib
4 Recruiting Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Condition: Multiple Myeloma
Interventions: Drug: Melphalan;   Drug: Bortezomib
5 Not yet recruiting Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat Velcade Dexamethasone
6 Recruiting Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone
7 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
8 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
9 Recruiting Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
10 Recruiting Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Bortezomib;   Drug: G-CSF
11 Recruiting Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
12 Recruiting Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Mozobil
13 Recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
14 Recruiting Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Bortezomib;   Drug: Dexamethasone
15 Recruiting Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plitidepsin;   Drug: Bortezomib;   Drug: Dexamethasone
16 Recruiting Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Bortezomib;   Drug: Dexamethasone
17 Recruiting Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Condition: Multiple Myeloma (MM)
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Lenalidomide
18 Recruiting Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Mitoxsnteone;   Drug: Thalidomide
19 Recruiting Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib-Melphalan;   Drug: Melphalan
20 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.